Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder

Deepika Dhawan, Bruce A. Craig, Liang Cheng, Paul W. Snyder, Sulma I. Mohammed, Jane C. Stewart, Rong Zheng, Rhoda A. Loman, Richard Foster, Deborah W. Knapp

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

High-grade invasive transitional cell carcinoma (InvTCC) kills >14,000 people yearly in the United States, and better therapy is needed. Cyclooxygenase-2 (Cox-2) is overexpressed in bladder cancer. Cox inhibitors have caused remission of InvTCC in animal studies, and cancer regression was associated with doubling of the apoptotic index in the tumor. The purpose of this study was to determine the apoptosis-inducing effects of celecoxib (a Cox-2 inhibitor) in InvTCC in humans. Patients (minimum of 10 with paired tumor samples) with InvTCC who had elected to undergo cystectomy were enrolled. The main study end point was induction of apoptosis in tumor tissues. Patients received celecoxib (400 mg twice daily p.o. for a minimum of 14 days) between the time of diagnosis [transurethral resection of bladder tumor (TURBT)] and the time of cystectomy (standard frontline treatment for InvTCC). Terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay and immunohistochemistry were done on TURBT and cystectomy samples. Of 13 cases treated with celecoxib, no residual invasive cancer was identified in 3 patients at the time of cystectomy (post celecoxib). Of the 10 patients with residual cancer, 7 had induction of apoptosis in their tumor. Induction of apoptosis was less frequent (3 of 13 cases; P < 0.04) in control patients not receiving a Cox inhibitor. Expression of vascular endothelial growth factor in the tumor cells decreased more frequently (P < 0.026) in the treated patients as compared with nontreated control cases. The biological effects of celecoxib treatment (increased apoptosis) justify further study of the antitumor effects of Cox-2 inhibitors in InvTCC.

Original languageEnglish
Pages (from-to)1371-1377
Number of pages7
JournalMolecular Cancer Therapeutics
Volume9
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Celecoxib
Transitional Cell Carcinoma
Urinary Bladder
Cystectomy
Apoptosis
Urinary Bladder Neoplasms
Neoplasms
Cyclooxygenase 2 Inhibitors
Residual Neoplasm
Therapeutics
DNA Nucleotidylexotransferase
Cyclooxygenase 2
Vascular Endothelial Growth Factor A
Immunohistochemistry

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. / Dhawan, Deepika; Craig, Bruce A.; Cheng, Liang; Snyder, Paul W.; Mohammed, Sulma I.; Stewart, Jane C.; Zheng, Rong; Loman, Rhoda A.; Foster, Richard; Knapp, Deborah W.

In: Molecular Cancer Therapeutics, Vol. 9, No. 5, 05.2010, p. 1371-1377.

Research output: Contribution to journalArticle

Dhawan, Deepika ; Craig, Bruce A. ; Cheng, Liang ; Snyder, Paul W. ; Mohammed, Sulma I. ; Stewart, Jane C. ; Zheng, Rong ; Loman, Rhoda A. ; Foster, Richard ; Knapp, Deborah W. / Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. In: Molecular Cancer Therapeutics. 2010 ; Vol. 9, No. 5. pp. 1371-1377.
@article{a3716c0f85bf4ef2b9bdfa9d560c6437,
title = "Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder",
abstract = "High-grade invasive transitional cell carcinoma (InvTCC) kills >14,000 people yearly in the United States, and better therapy is needed. Cyclooxygenase-2 (Cox-2) is overexpressed in bladder cancer. Cox inhibitors have caused remission of InvTCC in animal studies, and cancer regression was associated with doubling of the apoptotic index in the tumor. The purpose of this study was to determine the apoptosis-inducing effects of celecoxib (a Cox-2 inhibitor) in InvTCC in humans. Patients (minimum of 10 with paired tumor samples) with InvTCC who had elected to undergo cystectomy were enrolled. The main study end point was induction of apoptosis in tumor tissues. Patients received celecoxib (400 mg twice daily p.o. for a minimum of 14 days) between the time of diagnosis [transurethral resection of bladder tumor (TURBT)] and the time of cystectomy (standard frontline treatment for InvTCC). Terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay and immunohistochemistry were done on TURBT and cystectomy samples. Of 13 cases treated with celecoxib, no residual invasive cancer was identified in 3 patients at the time of cystectomy (post celecoxib). Of the 10 patients with residual cancer, 7 had induction of apoptosis in their tumor. Induction of apoptosis was less frequent (3 of 13 cases; P < 0.04) in control patients not receiving a Cox inhibitor. Expression of vascular endothelial growth factor in the tumor cells decreased more frequently (P < 0.026) in the treated patients as compared with nontreated control cases. The biological effects of celecoxib treatment (increased apoptosis) justify further study of the antitumor effects of Cox-2 inhibitors in InvTCC.",
author = "Deepika Dhawan and Craig, {Bruce A.} and Liang Cheng and Snyder, {Paul W.} and Mohammed, {Sulma I.} and Stewart, {Jane C.} and Rong Zheng and Loman, {Rhoda A.} and Richard Foster and Knapp, {Deborah W.}",
year = "2010",
month = "5",
doi = "10.1158/1535-7163.MCT-10-0049",
language = "English",
volume = "9",
pages = "1371--1377",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder

AU - Dhawan, Deepika

AU - Craig, Bruce A.

AU - Cheng, Liang

AU - Snyder, Paul W.

AU - Mohammed, Sulma I.

AU - Stewart, Jane C.

AU - Zheng, Rong

AU - Loman, Rhoda A.

AU - Foster, Richard

AU - Knapp, Deborah W.

PY - 2010/5

Y1 - 2010/5

N2 - High-grade invasive transitional cell carcinoma (InvTCC) kills >14,000 people yearly in the United States, and better therapy is needed. Cyclooxygenase-2 (Cox-2) is overexpressed in bladder cancer. Cox inhibitors have caused remission of InvTCC in animal studies, and cancer regression was associated with doubling of the apoptotic index in the tumor. The purpose of this study was to determine the apoptosis-inducing effects of celecoxib (a Cox-2 inhibitor) in InvTCC in humans. Patients (minimum of 10 with paired tumor samples) with InvTCC who had elected to undergo cystectomy were enrolled. The main study end point was induction of apoptosis in tumor tissues. Patients received celecoxib (400 mg twice daily p.o. for a minimum of 14 days) between the time of diagnosis [transurethral resection of bladder tumor (TURBT)] and the time of cystectomy (standard frontline treatment for InvTCC). Terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay and immunohistochemistry were done on TURBT and cystectomy samples. Of 13 cases treated with celecoxib, no residual invasive cancer was identified in 3 patients at the time of cystectomy (post celecoxib). Of the 10 patients with residual cancer, 7 had induction of apoptosis in their tumor. Induction of apoptosis was less frequent (3 of 13 cases; P < 0.04) in control patients not receiving a Cox inhibitor. Expression of vascular endothelial growth factor in the tumor cells decreased more frequently (P < 0.026) in the treated patients as compared with nontreated control cases. The biological effects of celecoxib treatment (increased apoptosis) justify further study of the antitumor effects of Cox-2 inhibitors in InvTCC.

AB - High-grade invasive transitional cell carcinoma (InvTCC) kills >14,000 people yearly in the United States, and better therapy is needed. Cyclooxygenase-2 (Cox-2) is overexpressed in bladder cancer. Cox inhibitors have caused remission of InvTCC in animal studies, and cancer regression was associated with doubling of the apoptotic index in the tumor. The purpose of this study was to determine the apoptosis-inducing effects of celecoxib (a Cox-2 inhibitor) in InvTCC in humans. Patients (minimum of 10 with paired tumor samples) with InvTCC who had elected to undergo cystectomy were enrolled. The main study end point was induction of apoptosis in tumor tissues. Patients received celecoxib (400 mg twice daily p.o. for a minimum of 14 days) between the time of diagnosis [transurethral resection of bladder tumor (TURBT)] and the time of cystectomy (standard frontline treatment for InvTCC). Terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay and immunohistochemistry were done on TURBT and cystectomy samples. Of 13 cases treated with celecoxib, no residual invasive cancer was identified in 3 patients at the time of cystectomy (post celecoxib). Of the 10 patients with residual cancer, 7 had induction of apoptosis in their tumor. Induction of apoptosis was less frequent (3 of 13 cases; P < 0.04) in control patients not receiving a Cox inhibitor. Expression of vascular endothelial growth factor in the tumor cells decreased more frequently (P < 0.026) in the treated patients as compared with nontreated control cases. The biological effects of celecoxib treatment (increased apoptosis) justify further study of the antitumor effects of Cox-2 inhibitors in InvTCC.

UR - http://www.scopus.com/inward/record.url?scp=77952184063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952184063&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-10-0049

DO - 10.1158/1535-7163.MCT-10-0049

M3 - Article

C2 - 20423998

AN - SCOPUS:77952184063

VL - 9

SP - 1371

EP - 1377

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -